TY - JOUR
T1 - Challenges of international oncology trial collaboration—a call to action
AU - Tang, Monica
AU - Joensuu, Heikki
AU - Simes, Robert J.
AU - Price, Timothy J.
AU - Yip, Sonia
AU - Hague, Wendy
AU - Sjoquist, Katrin M.
AU - Zalcberg, John
PY - 2019/10/1
Y1 - 2019/10/1
N2 - International collaboration in oncology trials has the potential to enhance clinical trial activity by expediting the recruitment of large patient populations, testing treatments in diverse populations and facilitating the study of rare tumours or specific molecular subtypes. However, a number of challenges continue to hinder the efficient and productive conduct of both commercial and non-commercial international clinical trials. These challenges include complex and burdensome regulatory requirements, the high cost of conducting trials, and logistical challenges associated with ethics review, drug supply and biospecimen collection and management. We propose solutions to promote oncology trial collaboration, such as regulatory reform, harmonisation of trial initiation and management processes and greater recognition and funding of academic (non-commercial) clinical trials. It is only through coordinated effort and leadership from researchers, regulators and those responsible for health systems that the full potential of international trial collaboration can be realised.
AB - International collaboration in oncology trials has the potential to enhance clinical trial activity by expediting the recruitment of large patient populations, testing treatments in diverse populations and facilitating the study of rare tumours or specific molecular subtypes. However, a number of challenges continue to hinder the efficient and productive conduct of both commercial and non-commercial international clinical trials. These challenges include complex and burdensome regulatory requirements, the high cost of conducting trials, and logistical challenges associated with ethics review, drug supply and biospecimen collection and management. We propose solutions to promote oncology trial collaboration, such as regulatory reform, harmonisation of trial initiation and management processes and greater recognition and funding of academic (non-commercial) clinical trials. It is only through coordinated effort and leadership from researchers, regulators and those responsible for health systems that the full potential of international trial collaboration can be realised.
UR - http://www.scopus.com/inward/record.url?scp=85070211873&partnerID=8YFLogxK
U2 - 10.1038/s41416-019-0532-4
DO - 10.1038/s41416-019-0532-4
M3 - Review Article
C2 - 31378784
AN - SCOPUS:85070211873
SN - 0007-0920
VL - 121
SP - 515
EP - 521
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 7
ER -